AR127743A1 - Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos - Google Patents
Anticuerpos capaces de unirse a cd27, variantes y usos de los mismosInfo
- Publication number
- AR127743A1 AR127743A1 ARP220102407A ARP220102407A AR127743A1 AR 127743 A1 AR127743 A1 AR 127743A1 AR P220102407 A ARP220102407 A AR P220102407A AR P220102407 A ARP220102407 A AR P220102407A AR 127743 A1 AR127743 A1 AR 127743A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- binding
- kit
- nucleic acid
- host cell
- Prior art date
Links
- 102100027207 CD27 antigen Human genes 0.000 title abstract 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical group 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 239000001963 growth medium Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención se refiere a anticuerpos capaces de unirse a CD27 humano y a variantes del mismo, que comprenden una región Fc modificada que comprende una o más mutaciones que potencian la interacción Fc-Fc del anticuerpo. La invención proporciona además composiciones farmacéuticas que comprenden los anticuerpos y el uso de los anticuerpos para procedimientos terapéuticos y de diagnóstico, en particular en la terapia del cáncer. Reivindicación 1: Un anticuerpo que comprende al menos una región de unión a antígeno capaz de unirse a CD27 humano, en donde dicho anticuerpo comprende una región variable de cadena pesada (VH) CDR1, CDR2 y CDR3 que comprende las secuencias que se presentan en SEQ ID Nº 5, 6 y 7, respectivamente, y una región variable de cadena liviana (VL) CDR1, CDR2 y CDR3 que comprende las secuencias que se presentan en SEQ ID Nº 9, 10 y 11, respectivamente. Reivindicación 45: Una secuencia de ácido nucleico aislada o una combinación de secuencias de ácido nucleico que codifican el anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 36. Reivindicación 58: Un vector de expresión que comprende la secuencia de ácido nucleico o una combinación de ella de acuerdo con cualquiera de las reivindicaciones 45 a 57. Reivindicación 60: Una célula huésped recombinante, que produce un anticuerpo como se define en cualquiera de las reivindicaciones 1 a 36, en donde opcionalmente la célula huésped comprende el vector de expresión de la reivindicación 58. Reivindicación 63: Un método para producir un anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 36, que comprende cultivar la célula huésped recombinante de la reivindicación 60 o 61 en un medio de cultivo y en condiciones adecuadas para producir el anticuerpo y, opcionalmente, purificar o aislar el anticuerpo del medio de cultivo. Reivindicación 64: Un kit de piezas, tal como un kit para usar como diagnóstico complementario / para identificar dentro de una población de pacientes a aquellos pacientes que tienen propensión a responder al tratamiento con un anticuerpo como se define en cualquiera de las reivindicaciones 1 a 36, que comprende un anticuerpo como se define en cualquiera de las reivindicaciones 1 a 36; e instrucciones de uso de dicho kit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21195118 | 2021-09-06 | ||
| EP22173126 | 2022-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127743A1 true AR127743A1 (es) | 2024-02-28 |
Family
ID=83400576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102407A AR127743A1 (es) | 2021-09-06 | 2022-09-06 | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20230109496A1 (es) |
| AR (1) | AR127743A1 (es) |
| AU (1) | AU2022338208A1 (es) |
| CA (1) | CA3231003A1 (es) |
| IL (1) | IL311141A (es) |
| TW (1) | TW202328192A (es) |
| WO (1) | WO2023031473A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023218046A1 (en) * | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US835A (en) | 1838-07-12 | X i i i x | ||
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| DK2270150T4 (da) | 1999-04-09 | 2019-08-26 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| PL218428B1 (pl) | 2000-10-06 | 2014-12-31 | Kyowa Hakko Kogyo Kk | Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| JPWO2002030954A1 (ja) | 2000-10-06 | 2004-02-19 | 協和醗酵工業株式会社 | 抗体を精製する方法 |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| ATE514717T1 (de) | 2002-07-18 | 2011-07-15 | Merus B V | Rekombinante produktion von antikörpermischungen |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| KR101799337B1 (ko) | 2007-06-21 | 2017-12-20 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이것의 사용 |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| MX2012006406A (es) | 2009-12-04 | 2012-07-25 | Genentech Inc | Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos. |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| EP2558498B1 (en) | 2010-04-13 | 2016-10-12 | Celldex Therapeutics, Inc. | Antibodies that bind human cd27 and uses thereof |
| KR101930964B1 (ko) | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법 |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2591001B1 (en) | 2010-07-09 | 2021-11-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to cd27 |
| US9834615B2 (en) | 2010-08-16 | 2017-12-05 | Novimmune Sa | Methods for the generation of multispecific and multivalent antibodies |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| BR112013001847A2 (pt) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica |
| DK2635607T3 (da) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | Stabilt heterodimert antistofdesign med mutationer i fc-domænet |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| JP6541974B2 (ja) | 2011-12-20 | 2019-07-10 | メディミューン，エルエルシー | 二重特異的抗体足場用改変ポリペプチド |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| CA2882296A1 (en) | 2012-08-20 | 2014-02-27 | Gliknik Inc. | Molecules with antigen binding and polyvalent fc gamma receptor binding activity |
| EA201500741A1 (ru) | 2013-01-10 | 2016-01-29 | Генмаб Б.В. | ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ |
| LT2970456T (lt) | 2013-03-14 | 2021-08-10 | Translate Bio, Inc. | Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui |
| RS57316B1 (sr) | 2013-03-15 | 2018-08-31 | Translate Bio Inc | Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija |
| CA2945882A1 (en) | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Multimeric fc proteins |
| EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
| DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
| EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| JP7086870B2 (ja) | 2016-06-30 | 2022-06-20 | アルブータス・バイオファーマー・コーポレイション | メッセンジャーｒｎａを送達するための組成物及び方法 |
| KR102587941B1 (ko) | 2016-08-12 | 2023-10-11 | 얀센 바이오테크 인코포레이티드 | 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| MA46700A (fr) * | 2016-11-01 | 2021-05-19 | Genmab Bv | Variants polypeptidiques et ses utilisations |
| WO2018114879A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
| US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| BR112019009839A2 (pt) | 2016-12-21 | 2019-09-17 | Hoffmann La Roche | método para a produção enzimática de um anticorpo e anticorpo |
| AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
| BR112019015900A2 (pt) | 2017-02-10 | 2020-04-07 | Genmab B.V. | polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição |
| EP3743440A1 (en) | 2018-01-24 | 2020-12-02 | Genmab B.V. | Polypeptide variants and uses thereof |
| WO2019195452A1 (en) | 2018-04-04 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
| MA52951A (fr) | 2018-06-22 | 2021-04-28 | Genmab Holding B V | Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci |
| CN114650829A (zh) * | 2019-09-05 | 2022-06-21 | 索伦托药业有限公司 | 结合bcma的二聚体抗原受体(dar) |
-
2022
- 2022-09-06 CA CA3231003A patent/CA3231003A1/en active Pending
- 2022-09-06 IL IL311141A patent/IL311141A/en unknown
- 2022-09-06 WO PCT/EP2022/074696 patent/WO2023031473A1/en active Application Filing
- 2022-09-06 US US17/929,799 patent/US20230109496A1/en active Pending
- 2022-09-06 TW TW111133765A patent/TW202328192A/zh unknown
- 2022-09-06 AU AU2022338208A patent/AU2022338208A1/en active Pending
- 2022-09-06 AR ARP220102407A patent/AR127743A1/es unknown
- 2022-11-14 US US18/055,362 patent/US20230212301A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022338208A1 (en) | 2024-03-21 |
| TW202328192A (zh) | 2023-07-16 |
| IL311141A (en) | 2024-04-01 |
| WO2023031473A1 (en) | 2023-03-09 |
| US20230109496A1 (en) | 2023-04-06 |
| US20230212301A1 (en) | 2023-07-06 |
| CA3231003A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2669395T3 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleína | |
| ES2764833T3 (es) | Anticuerpos contra TEM8 y su uso | |
| JP2019511222A5 (es) | ||
| JP2020531515A (ja) | 癌治療向け免疫療法とサイトカイン制御療法の組合せ | |
| CN110505877A (zh) | Rna癌症疫苗 | |
| CA3014885A1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
| CL2004000534A1 (es) | Anticuerpo aislado selectivo para un receptor de il-21 (o receptor mu-1); polinucleotido que lo codifica; vector y celula huesped que lo expresa; metodo de preparacion; composicion farmaceutica; kit que lo contiene; y usos en la preparacion de medica | |
| JP2018507208A (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| CN105026428A (zh) | PD-l抗体、其抗原结合片段及其医药用途 | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CN104994873A (zh) | 人单克隆抗-pd-l1抗体和使用方法 | |
| AR062223A1 (es) | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas | |
| ITMI20071522A1 (it) | Vaccino idiotipico | |
| EP3666793A3 (en) | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 | |
| JP2018503600A5 (es) | ||
| AR127743A1 (es) | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos | |
| MX2020003945A (es) | Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente . | |
| CN106999556A (zh) | 细胞因子诱导的杀伤细胞的双特异性抗体介导的癌症治疗 | |
| AR111265A1 (es) | Combinaciones farmacéuticas, kit, célula huésped, uso | |
| ECSP15028696A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos | |
| JP2015521587A (ja) | ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 | |
| AR118997A1 (es) | Partículas virales modificadas y usos de estas | |
| BR112021008263A2 (pt) | materiais e métodos para tratamento de câncer | |
| JP2019511246A (ja) | 改変ｈｓｐ７０ドメインを有する抗原結合融合タンパク質 | |
| Burton et al. | A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder |